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Abstract
Because sexual transmission of HIV occurs across mucosal membranes, understanding the immune responses of the genital
mucosa to vaccines may contribute knowledge to finding an effective candidate HIV vaccine. We describe the uptake of
rectal secretion, cervical secretion and seminal mucosal secretion sampling amongst volunteers in a Phase 1b HIV vaccine
trial. Age at screening, gender, study site and the designation of the person conducting the informed consent procedure
were collected for volunteers who screened for the HVTN 097 study. A total of 211 volunteers (54% female) were screened
at three sites in South Africa: Soweto (n = 70, 33%), Cape Town (n = 68, 32%) and Klerksdorp (n = 73, 35%). Overall uptake of
optional mucosal sampling amongst trial volunteers was 71% (n = 149). Compared to Cape Town, volunteers from Soweto
and Klerksdorp were less likely to consent to sampling (Soweto OR 0.08 CI: 0.03–0.25 p,0.001 and Klerksdorp OR 0.13 CI:
0.04–0.41 p = 0.001). In contrast, volunteers over 25 years of age were 2.39 times more likely to consent than younger
volunteers (CI: 1.13–5.08, p = 0.02). Further studies are required to better understand the cultural, demographic and
sociobehavioral factors which influence willingness to participate in mucosal sampling in HIV prevention studies.
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Introduction
Despite the upscale of HIV prevention strategies like male
medical circumcision, there were an estimated 2.1 million new
HIV infections globally in 2013 [1]. In South Africa, the country
with the highest number of people living with HIV, where
heterosexual HIV transmission is predominant, there were an
estimated 340,000 new infections in 2013 alone [1].Sexual
transmission remains the driver of the AIDS epidemic, especially
in Sub-Saharan Africa where the burden is highest [1].
Developing a multifaceted package of prevention tools to curb
the epidemic is crucial, and an efficacious HIV vaccine will have a
major contribution toward reaching the UNAIDS goal of zero
new infections [2].
The landmark RV 144 Thai trial which investigated the use of a
recombinant canarypox vector vaccine, ALVAC, in combination
with recombinant glycoprotein 120 subunit vaccine, AIDSVAX,
was the first HIV vaccine trial to show efficacy [3]. The HIV
Vaccines Trials Network (HVTN) 097 trial is a Phase 1b study
designed to assess the safety and immunogenicity of the HIV
Clade B/E Thai regimen vaccines in a South African population
where the predominant HIV strain is Clade C.
Because sexual transmission of HIV occurs across mucosal
membranes, much work has been done to elucidate the innate
factors central to genital mucosal immunity [4,5]. Several mucosal
innate immune factors with in vitro anti-HIV properties, such as
the immune proteins Secretory Leukocyte Protease Inhibitor
(SLPI), Trappin-2, Lactoferrin and Defensins a and b, have been
explored as possible immune correlates of protection in vivo in at-
risk populations including men who have sex with men, highly
exposed persistently seronegative women and HIV exposed infants
[4]. As research continues, understanding the mucosal immune
response to vaccines in development may contribute knowledge to
finding an effective candidate [6,7]. Preclinical studies in rhesus
macaques have shown that systemic vaccination against Simian
Immunodeficiency Syndrome (SIV) induced SIV specific immune
responses in mucosal tissues, which were associated with decreased
cellular viral loads [8,9] One of the primary aims of RV 306, a
follow-up study to the RV144 trial currently recruiting partici-
pants, is to characterise vaccine induced immune responses to the
RV144 regimen in systemic and mucosal compartments [10].
Similarly, HVTN 097 seeks to evaluate the HIV specific immune
correlates of protection identified in RV144 in the mucosal
compartment. Therefore various combinations of optional muco-
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sal sampling of rectal, cervical and seminal compartments may be
performed on participants in HIV vaccine trials which investigate
mucosal responses.
Rectal secretion, cervical secretion and semen sampling are the
current methods of mucosal sampling validated by the HVTN
mucosal immunology group [11,12]. These are benign procedures
with minimal side effects, mainly minor discomfort. Other side
effects of cervical secretion sampling are similar to those associated
with Pap smear testing including minor bleeding, pain and
abdominal cramping but these are uncommon. Rectal secretion
sampling may also result in minor bleeding although this is also
seldom seen. While all procedures may cause embarrassment or
anxiety, procedures are optional and consent can be withdrawn at
any time without affecting participation in the study.
Although the literature supports the expressed willingness of
communities to participate in hypothetical preventive HIV vaccine
trials [13–18], to the authors’ knowledge, no literature to date
describes the willingness of those who screen for such studies to
participate in mucosal sampling procedures. We describe the
actual written willingness of volunteers who were screened for
HVTN 097 to undergo optional rectal secretion, cervical secretion
and seminal mucosal secretion sampling.
Methods
This cross-sectional study was conducted using non-trial data
collected from the three South African sites which screened
participants for HVTN 097 located in Cape Town, Western Cape
province (HIV prevalence 5.0%); Klerksdorp, North West
province (HIV prevalence 13.3%) and Soweto, Gauteng province
(HIV prevalence 12.4%) [19]. Screening for HVTN 097 took
place between June 2013 and November 2013. As shown in
Figure 1, a total of 211 volunteers were screened and 100 were
enrolled per protocol. Enrolled participants remained in active
follow-up throughout data collection and analysis for this report,
which occurred between December 2013 and February 2014.
HVTN 097 was a phase 1b randomized double blind placebo
controlled clinical trial to evaluate the safety and immunogenicity
of the RV144 vaccine regimen in healthy, HIV-1 uninfected adult
participants at low risk for acquiring HIV at three sites in South
Africa: Soweto, Cape Town and Klerksdorp. Low risk was defined
as being sexually abstinent, or in a mutually monogamous
relationship with a partner of known HIV-uninfected status, or
having one partner believed to be HIV-uninfected with whom he/
she regularly used condoms for vaginal or anal intercourse, during
the 12 months prior to enrolment into HVTN 097. Volunteers for
the study provided written informed consent simultaneously for
the study and optional mucosal sampling procedures prior to
beginning screening processes. At the time of consent, all
volunteers were given the option to undergo rectal secretion
and/or cervical secretion (female)/seminal (male) mucosal secre-
tion sampling at three time points during the study: at enrolment
to provide baseline values of mucosal immunity, midway (Day
210) and toward study completion (Day 394) to provide
information on the durability of vaccine-induced mucosal immu-
nity. Volunteers could refuse consent to any or all of the
procedures without affecting their eligibility to enrol in the study.
The Participant Information Leaflet described risks (e.g. short-
lived discomfort and minor bleeding), benefits (testing and
treatment as required for sexually transmitted infections (STIs))
and the procedures involved in sampling. Rectal secretion
sampling involved anoscope insertion into the rectum and
absorption of fluids by sponge for 5 minutes. For cervical secretion
sampling, vaginal speculum insertion was followed by sponge
placement into the endocervix. Rectal and cervical secretion
sampling were performed by a study physician. Semen sampling
involved masturbation into a container, which could be done at
the clinical research site or at home depending on volunteer
preference.
Eligibility for mucosal sample collection included absence of
local lesions and no sexual intercourse or use of topical products
within 48 hours of sampling. For cervical secretion sampling,
participants could not be menstruating, had to have a negative
pregnancy test and must have had a normal Pap smear test result
within the 3 years prior to the first sampling procedure. Female
volunteers who had not had a recent Pap smear but agreed to
cervical secretion sampling had Pap smears performed on site
(Soweto and Cape Town) or were referred to nearby facilities
(Klerksdorp).
Information was collected by site coordinators who reviewed
volunteer informed consent documents obtained in local languag-
es. Birth date and sex at birth demographics were collated from
volunteer records. Qualitative sociobehavioral data was not
collected as this was not included in the study protocol. We
collated the following information amongst all volunteers who
consented to screen for the HVTN 097 trial regardless of their
final study or sampling eligibility status, or their decision on
whether or not to participate in any mucosal sampling procedures:
volunteer age, sex at birth, research site and designation of staff
conducting consent.
Statistical analysis
Age was analysed descriptively as a continuous variable and
then categorised into the age-groups 18–24, 25–30 and .30 years.
Frequencies and their proportions were determined for all
categorical variables, and presented overall and by sex at birth.
Comparison of categorical variables by sex at birth was done using
the chi-square test of proportions.
Predictors of consenting to any mucosal sampling strategy were
determined using univariate and multivariate logistic regression.
Statistical analysis assumed a two-sided 5% significance level and
was performed using SAS Enterprise Guide version 5.1 (Analysis
Software Institute, Cary, NC, USA).
Ethical Considerations
HVTN 097 received approval from the University of the
Witwatersrand Human Research Ethics Committee and the
University of Cape Town Ethics Committee.
Results
A total of 211 volunteers (54% female) were screened at the
three sites: Soweto (n = 70, 33%), Cape Town (n = 68, 32%) and
Klerksdorp (n = 73, 35%). The median age was 22.6 years (IQR:
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20.4–26.9), and the majority were consented by trained lay
counsellors (n = 196, 93%). Soweto enrolled significantly more
males than females, whilst the opposite was true of Cape Town
(Table 1).
Twenty nine percent (62/211) of volunteers who screened for
participation in HVTN 097 declined all mucosal sampling
procedures. Of the 100 volunteers eventually enrolled into HVTN
097, 68% (n = 68) had provided consent for mucosal sampling.
This was not significantly different to the 73% (n = 81) of screening
failures who had provided consent for mucosal sampling (p = 0.43).
Uptake of combination sampling was not significantly different to
any single sampling method alone (p = 0.37). The proportion of
females consenting to procedures that included cervical secretion
sampling was similar between the two sites (Soweto and Cape
Town) that performed in-house Pap smear testing versus the site
(Klerksdorp) which referred out for Pap (57/74 (77%) vs. 32/40
(80%); p = 0.71). Although more women than men consented to
mucosal sampling procedures (n = 90, 79% vs. n = 59, 61%;
p = 0.004), sex at birth was not identified as a predictor for
sampling consent in multivariate analysis. However, 47% (n = 54)
of females consented to rectal secretion sampling and 77% (n = 88)
to cervical secretion sampling. And for males, 33% (n = 32)
consented to rectal secretion sampling and 55% (n = 53) to semen
sampling.
In the multivariate logistic regression controlling for the
designation of person conducting informed consent shown in
table 2, those between 18–24 years old (OR: 0.418, CI: 0.197–
0.888), and those recruited in Soweto (OR: 0.078, CI: 0.025–
0.250), and Klerksdorp (OR: 0.133, CI: 0.042–0.414) had a lower
odds of consenting to any mucosal sampling strategy.
Discussion
To our knowledge, this is the first paper describing consent to
optional mucosal sampling procedures in HIV vaccine trials.
Overall uptake of optional mucosal sampling amongst HVTN 097
vaccine trial volunteers was 71% despite the personal and invasive
nature of the procedure. Our study finds that there were regional
differences in the uptake of mucosal sampling at the various sites,
suggesting different sociocultural preferences, differences in local
site staff interaction with volunteers, or differences in consenting
procedures, for example group discussions prior to individual
consent and degree of privacy in the rooms used to discuss
information pamphlets. Older volunteers were significantly more
likely to consent to mucosal procedures than younger individuals.
Though work has not been done to explore the motivators for
consenting to mucosal sampling, previous studies investigating
expressed willingness to participate (WTP) in hypothetical HIV
vaccine trials may shed some light. In a previous study at the
Soweto site, it was demonstrated that less exposure to social
stressors was associated with higher expressed WTP in HIV
biomedical prevention trials in adolescents aged 16–18 years [15].
At the same site, adolescents rated the following benefits as ‘‘very
important’’ in expressing a WTP in a hypothetical trial: receiving
current information about HIV research, doing something to
honor people who have HIV or have died of AIDS, obtaining free
HIV counseling and testing, possibility of protection against HIV,
and improving motivation to avoid risky behavior. Unlike our
study which measured actual consent to a procedure, this
adolescent vaccine trial preparedness study showed no significant
differences in expressed WTP in a hypothetical trial by sex at birth
[20]. In one study in Cape Town, although more adults reported
expressed WTP than adolescents at the start of the study, this
Table 1. Demographics of all volunteers screened for the HVTN 097 trial.
Variable Total sample (n = 211) Females (n = 114) Males (n = 97) p-value
Median Age (IQR) in years 22.6 (20.4–26.9) 22.8 (20.5–27.1) 22.6 (20.4–26.6) 0.87
Age
18–24 years (%) 132 (63) 71 (62) 61 (63) 0.93
25–30 years (%) 57 (27) 31 (27) 26 (27) 0.95
.30 years (%) 22 (10) 12 (11) 10 (10) 0.96
Site
Soweto (%) 70 (33) 26 (23) 44 (45) 0.001
Klerksdorp (%) 73 (35) 40 (35) 33 (34) 0.87
Cape Town (%) 68 (32) 48 (42) 20 (21) 0.001
Designation of person conducting informed consent
Counsellor (%) 196 (93) 112 (98) 84 (87) 0.001
Clinician (Doctor/Nurse) (%) 15 (7) 2 (2) 13 (13) -
Enrolled into study
Yes (%) 100 (47) 65 (57) 46 (47) 0.16
No (%) 111 (53) 49 (43) 51 (53) -
Consented to
Any sampling (%) 149 (71) 90 (79) 59 (61) 0.004
Rectal secretions only (%) 6 (3) 1 (0.8) 5 (5) -
Cervical secretion or Semen only (%) 63 (30) 36 (32) 27 (28) 0.55
Rectal secretion +Cervical secretion/Semen (%) 80 (38) 53 (46) 27 (28) 0.005
None (%) 62 (29) 24 (21) 38 (39) 0.004
doi:10.1371/journal.pone.0112303.t001
Mucosal Sampling Uptake
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difference was eliminated after attending two educational work-
shops on HIV, vaccines and vaccine trials [16]. This corroborated
other Cape Town data which demonstrated that increasing
knowledge about HIV vaccines is associated with higher expressed
WTP in hypothetical HIV vaccine trials [14].
Another Cape Town study showed that five factors affected
expressed WTP in hypothetical vaccine trials: personal costs, safety
and convenience, stigmatization, personal gains, and social
approval and trust [17]. The regional differences of consenting
to mucosal sampling shown in our study may be explained by
some of these factors due to variations in community character-
istics.
There may also be factors related to mucosal sampling which
are different to simply participating in a vaccine trial which could
affect mucosal sampling uptake, for example mistrust of staff
handling these sensitive samples or psychosocial discomfort.
Although our study is not able to assess whether consenting to
mucosal sampling procedures translates into actual participation in
these procedures, a vaccine preparedness study conducted in the
United States of America found that significantly more partici-
pants who expressed definite willingness to participate in a
hypothetical vaccine trial were eventually enrolled compared to
those who expressed probable willingness or probable/definite
unwillingness. However, ultimately only 20% of those participants
who had stated hypothetical willingness to participate did actually
enroll in the HIV vaccine trial indicating that willingness to
participate may overestimate actual participation [21].
STI testing is not routinely available in the public health sector
in South Africa. STI treatment is only provided to symptomatic
persons who present for care using a World Health Organization
based syndromic management approach, which involves the use of
multiple drugs to cover the most likely causes of infection [22,23].
Although this study enrolled individuals whose sexual behavior
was considered to be low risk for acquiring HIV and therefore also
other STIs, access to free STI testing and specific treatment may
have played a role in promoting uptake of sampling.
For women in our study, one of the benefits of consenting to
cervical secretion procedures was free access to cervical cancer
screening by Pap smear. In the South African National Guideline
for Cervical Cancer Screening, free public sector Pap smear
testing is available to HIV-uninfected women only from the age of
30 years and then every 10 years thereafter to a maximum of three
lifetime tests, unless abnormalities warranting further investiga-
tions are detected [24].
Cultural factors may play a role in the uptake of semen
sampling. Various studies noted male anxiety around masturba-
tion [25–27], which would pose a barrier to semen sampling in
vaccine trials. In Sri Lanka for example semen loss by
masturbation or nocturnal emission was perceived as detrimental
to mental and physical health [27]. However, the authors are not
aware of any similar research in the South African context.
A strength of our study is that, unlike many other studies
referenced, it does not describe expressed WTP but rather
measures factors associated with actual consent to procedures in
South African sites. However, owing to the cross-sectional nature
of the study, we are unable to account for consent withdrawal over
time for which longitudinal data would be required. A limitation of
our study is that we did not collect reasons which motivate or
impede expressed WTP.
Further studies are required to better understand the cultural,
demographic and sociobehavioral factors which influence willing-
ness to participate in mucosal sampling in HIV prevention studies.
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